Professor, Oncology, Karmanos Cancer Institute/Wayne State University School of Medicine
Oncology
Dr. Shirish M. Gadgeel, MD
|
|
Give Review
Shirish Gadgeel practices Oncology. He studied medicine at Wayne State University School of Medicine. Wayne State University School of Medicine has a rank of 63 in research and a 85 in primary care He has 1 awards "Most Compassionate Doctor". Shirish Gadgeel has written publications. He has 81 publications published with PubMed. The lastest publication is: 'Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.' Doctor Shirish M. Gadgeel, MD is registered with Medicare and accepts Medicare payments.
Publications
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung Cancer: a single-group, multicentre, phase 2 trial.
- Whole-exome sequencing reveals genetic variability among lung Cancer cases subphenotyped for emphysema.
- Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
- A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung Cancer.
- Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment...
- Racial diversity of actionable mutations in non-small cell lung Cancer.
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung Cancer (AF-002J...
- Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Can...
- Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.
- Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung Cancer cells to pemetrexed.
- Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung Cancer patients.
- Radioprotection of Lung Tissue by Soy Isoflavones.
- Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced Cancers: South West...
- New targets in non-small cell lung Cancer.
- Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung Cancer.
- Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung Cancer.
- Erlotinib resistance in lung Cancer: current progress and future perspectives.
- Modern staging of small cell lung Cancer.
- Percutaneous cryoablation of metastatic lesions from non-small-Cell lung carcinoma: initial survival, local control, and cost observations.
- Soy isoflavones radiosensitize lung Cancer while mitigating normal tissue injury.
- Safety Profile and Tolerability of Antiangiogenic Agents in Non-Small-Cell Lung Cancer.
- XL647-A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatm...
- Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509.
- Analysis of Lung Cancer Patients Enrolled in CTEP (Cancer Therapy Evaluation Program)-Sponsored Phase I Trials.
- Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer.
- The Optimal Chemotherapy for Stage III Non-Small Cell Lung Cancer Patients.
- Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung Cancer.
- Hope and Realism: The Perfect Balance?
- Soy Isoflavones Augment Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung Cancer.
- Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung Cancer.
- A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung Cancer.
- Subdividing NSCLC: reflections on the past, present, and future of lung Cancer therapy.
- Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States.
- Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung Cancer cell lines.
- Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung Cancer.
- Targeted therapy in lung Cancer: the good, the bad, and the ugly.
- Phase II study of celecoxib and docetaxel in non-small cell lung Cancer (NSCLC) patients with progression after platinum-based therapy.
- Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung Cancer.
- Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid Tumors.
- Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung Cancer may be dependent on the EGFR mutational status of...
- Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients...
- Adjuvant treatment of non-small-cell lung Cancer: how do we improve the cure rates further?
- Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung Cancer.
- Predictors of enrollment in lung Cancer clinical trials.
- Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
- Novel combinations using pemetrexed in Malignant mesothelioma.
- Racial differences in lung Cancer.
- Phase II study of paclitaxel and carboplatin in patients with advanced gastric Cancer.
- Biochemotherapy of Melanoma.
- Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones.
- Fibroblast growth factor receptor 1 amplification in non-small cell lung Cancer by quantitative real-time PCR.
- Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung Cancer.
- Up-regulation of sonic hedgehog contributes to TGF-?1-induced epithelial to mesenchymal transition in NSCLC Cells.
- Cediranib in combination with various antiCancer regimens: results of a phase I multi-cohort study.
- The natural tumor suppressor protein maspin and potential application in non small cell lung Cancer.
- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung Cancer.
- Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung Cancer.
- A phase I study of flavopiridol and docetaxel.
- An educational video to increase clinical trials enrollment among lung Cancer patients.
- Chronic obstructive lung diseases and risk of non-small cell lung Cancer in women.
- An educational video to increase clinical trials enrollment among breast Cancer patients.
- Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced Cancer.
- Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung Cancer.
- Phase I study of bryostatin 1 and gemcitabine.
- A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor.
- A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung Cancer following treatment with platinum-based chemotherapy.
- Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
- Impact of race in lung Cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database.
- Cost-effectiveness and lung Cancer clinical trials.
- A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.
- Lung Cancer in patients < 50 years of age: the experience of an academic multidisciplinary program.
- Lung Cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.
- A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric Cancer.
- Growth inhibition and induction of apoptosis by fenretinide in small-cell lung Cancer cell lines.
- Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous Cell carcinoma of the head and neck.
- Retrospective review of Cancer patients > or =80 years old treated with chemotherapy at a comprehensive Cancer center.
- Crizotinib: an anaplastic Lymphoma kinase inhibitor.
- Adjuvant therapy for resected non-small cell lung Cancer.
- Parameters for individualizing systemic therapy in non-small cell lung Cancer.
Schools
University Of Mumbai
Laguardia Hospital
Detroit Mc Wayne State University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Most Compassionate Doctor
Education
-
Wayne State University School of Medicine -
Grant Medical College
Hospital
-
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1033156534 | |
| NPPES Provider LastName | GADGEEL | |
| NPPES Provider FirstName | SHIRISH | |
| NPPES Provider ZIPCode | 482012013 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 827.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 171.0 | |
| Percent Opioid Claims | 20.68 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033156534 |
| Last Name Of The Provider | GADGEEL |
| First Name Of The Provider | SHIRISH |
| View All |
Similar Doctors
|
|
Dr. Mark Edelstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven J. Gamalski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony F. Shields, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Elisabeth I. Heath, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ammar Sukari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eudoro Coello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shin Ogita, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Belisario A. Arango, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Salman Chaudhry, MB BS |